P380: EX VIVO IMMUNE ACTIVATION WITH THE MACROPHAGE-TARGETING IMMUNOTHERAPY, ANTI-CLEVER-1 ANTIBODY BEXMARILIMAB, IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME

• S. Aakko,
• A. Ylitalo,
• H. Kuusanmäki,
• M. Björkman,
• J. Mandelin,
• J. Jalkanen,
• M.-L. Fjällskog,
• C. Heckman,
• M. Hollmén,
• M. Kontro

Affiliations

S. Aakko

1 Faron Pharmaceuticals Ltd, Turku

A. Ylitalo

3 MediCity Research Laboratory, University of Turku, Turku

H. Kuusanmäki

2 Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki

M. Björkman

1 Faron Pharmaceuticals Ltd, Turku

J. Mandelin

1 Faron Pharmaceuticals Ltd, Turku

J. Jalkanen

1 Faron Pharmaceuticals Ltd, Turku

M.-L. Fjällskog

1 Faron Pharmaceuticals Ltd, Turku

C. Heckman

2 Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki

M. Hollmén

3 MediCity Research Laboratory, University of Turku, Turku

M. Kontro

2 Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki